The Best Diabetes or Insulin Stock Plays? NVO, LLY, SNY, MRK, AMLN, PODD & MNKD
posted on
Jul 24, 2012 10:33AM
"MannKind Corporation (NASDAQ: MNKD). A biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products, MannKind Corporation’s lead investigational product candidate is AFREZZA® - a novel, ultra rapid-acting mealtime insulin therapy. AFREZZA® is already in late stage clinical investigation for the treatment of adults who have type 1 or type 2 diabetes for the control of hyperglycemia but what makes MannKind Corporation even more interesting is the fact that its CEO Alfred or Al Mann became a billionaire by founding a series of startups that eventually got acquired and one of these companies was Minimed – a maker of insulin pumps that was bought out by Medtronic, Inc. (NYSE: MDT) in a $3 billion-plus acquisition. Moreover and in recent months, insiders like Al Mann have been buying shares of MannKind Corporation – a bullish sign for the company. MannKind Corporation has a market cap of $432.98 million plus the stock is up 4% since the start of the year.
The Bottom Line. So which is the best insulin stock play, Novo Nordisk (NVO), Eli Lilly & Co. (LLY), Sanofi SA (SNY), Merck & Co. (MRK), Amylin Pharmaceuticals (AMLN), Insulet Corporation (PODD) or MannKind Corporation (MNKD)? That really depends upon what you as an investor are looking for. "
http://www.smallcapnetwork.com/The-Best-Diabetes-or-Insulin-Stock-Plays-NVO-LLY-SNY-MRK-AMLN-PODD-MNKD/s/via/3414/article/view/p/mid/1/id/834/
